Tempus AI Inc. (NASDAQ: TEM) announced an expanded multi-year collaboration with Gilead Sciences Inc. (NASDAQ: GILD) to advance Gilead's oncology pipeline development through artificial intelligence and real-world evidence.

The expanded agreement provides Gilead with enterprise-wide access to Tempus' AI-driven Lens platform and broader datasets across multiple indications. Gilead has previously used Tempus' de-identified multimodal data repository for oncology research and development initiatives including trial design, indication selection, biomarker strategy, health outcomes analysis and clinical real-world evidence.

The collaboration integrates dedicated Tempus analytical services with access to the company's multimodal data library. Tempus operates one of the world's largest libraries of multimodal data and provides AI-enabled precision medicine solutions to physicians and pharmaceutical companies.

"We are excited to announce this expanded partnership with Tempus that reflects our shared priority of putting patients at the heart of innovation," said Patrick Loerch, senior vice president of clinical data science at Gilead Sciences. "By combining Gilead's scientific expertise with Tempus' real world data insights in oncology, we aim to maximize generation of key insights to help inform clinical decision making and ultimately improve care for cancer patients."

Ryan Fukushima, chief executive officer of Tempus Data & Apps, said the collaboration aims to provide multimodal data depth to uncover biological insights and help navigate data points to increase the probability of success for therapeutic development.

The announcement was made through a company press release statement.